These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 34272171)

  • 41. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
    Sureau L; Orvain C; Ianotto JC; Ugo V; Kiladjian JJ; Luque Paz D; Riou J
    Blood Cancer J; 2021 Jul; 11(7):135. PubMed ID: 34315858
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
    Patel AA; Odenike O
    Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Investigational Janus kinase inhibitors in development for myelofibrosis.
    Bose P; Abou Zahr A; Verstovsek S
    Expert Opin Investig Drugs; 2017 Jun; 26(6):723-734. PubMed ID: 28441920
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.
    Harrison CN; Talpaz M; Mead AJ
    Leuk Lymphoma; 2016 Oct; 57(10):2259-67. PubMed ID: 27463690
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The new landscape of therapy for myelofibrosis.
    Gowin K; Emanuel R; Geyer H; Mesa RA
    Curr Hematol Malig Rep; 2013 Dec; 8(4):325-32. PubMed ID: 24101258
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Next Generation Therapeutics for the Treatment of Myelofibrosis.
    Tremblay D; Mascarenhas J
    Cells; 2021 Apr; 10(5):. PubMed ID: 33925695
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis.
    Palmer J; Mesa R
    Ther Adv Hematol; 2020; 11():2040620720925201. PubMed ID: 32477483
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.
    Scherber RM; Mesa RA
    Blood Rev; 2020 Jul; 42():100716. PubMed ID: 32593470
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Advances in pharmacotherapy for myelofibrosis: what is the current state of play?
    Tiribelli M; Morelli G; Bonifacio M
    Expert Opin Pharmacother; 2024 Apr; 25(6):743-754. PubMed ID: 38738513
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of anemia in myelofibrosis: focusing on novel therapeutic options.
    Arslan Davulcu E; Oğuz MB; Kılıç E; Eşkazan AE
    Expert Opin Investig Drugs; 2024 Jan; 33(1):27-37. PubMed ID: 38073183
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
    Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
    Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modern management of splenomegaly in patients with myelofibrosis.
    Tremblay D; Schwartz M; Bakst R; Patel R; Schiano T; Kremyanskaya M; Hoffman R; Mascarenhas J
    Ann Hematol; 2020 Jul; 99(7):1441-1451. PubMed ID: 32417942
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
    Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
    PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
    Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
    Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
    Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
    J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Investigational non-JAK inhibitors for chronic phase myelofibrosis.
    Bankar A; Gupta V
    Expert Opin Investig Drugs; 2020 May; 29(5):461-474. PubMed ID: 32245330
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
    Arana Yi C; Tam CS; Verstovsek S
    Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes.
    Mascarenhas J; Harrison C; Schuler TA; Liassou D; Garretson M; Miller TA; Mahadevan S; McBride A; Tang D; DeGutis IS; Abraham P; Kish J; Feinberg BA; Gerds AT
    Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):122-132. PubMed ID: 37839939
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Managing patients with myelofibrosis and thrombocytopenia.
    Yilmaz M; Verstovsek S
    Expert Rev Hematol; 2022 Mar; 15(3):233-241. PubMed ID: 35316110
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Practical management of patients with myelofibrosis receiving ruxolitinib.
    Harrison C; Mesa R; Ross D; Mead A; Keohane C; Gotlib J; Verstovsek S
    Expert Rev Hematol; 2013 Oct; 6(5):511-23. PubMed ID: 24083419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.